<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191216045760N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-15</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Curcuma and Russian olive in the Treatment of Knee Osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of Turmeric extract (Curcuma) versus Russian olive extract on the pain, function and quality of life in the patients with knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-02-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44316</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using a computer-based randomization method, 50 people will be randomly assigned in to two groups (Group A, N=25 and Group B, N=25). The list will be given to the senior researcher. Patients will be assigned in to treatment A or treatment B by a designated peer after recruitment (by sequential sampling) according to the determined numbers, Blinding description: In this study, the primary investigator and supervisor are considered as physicians who are fully aware of the purpose of the study and the type of treatment. Patients will not be informed about the statistical purposes of the study and how the treatments are supposed to be compared. Patients will be informed of the name of their medication (as the treatment will be performed on an outpatient basis with the drug capsules available on the market). The researcher who evaluates the outcomes, as well as the statistical consultant and data analyst, does not know about the treatment  A or B (Elartrit or curcumin, respectively) and the patients' names. Therefore, this study is a single-blind study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Osteoarthritis of knee.</hc_freetext>
      <i_freetext>Intervention 1: The itervention group will be orally treated with 250 mg Elartrit capsules (containing Russian olive extract) of Reyhaneh Isfahan Pharmaceutical Company (every 12 hours for 15 days, after meal). In addition, they will be instructed to perform stretching the hamstring and calf muscles as well as the quadriceps strengthening exercises for 30 days in the morning, noon and night, three times in each set and doing those for 30 seconds each time. Intervention 2: The control group will be orally treated with 370 mg curcumin capsules of Razak Pharmaceutical Company (every 12 hours for 15 days, after meal). In addition, they will be instructed to perform stretching the hamstring and calf muscles as well as the quadriceps strengthening exercises for 30 days in the morning, noon and night, three times in each set and doing those for 30 seconds each time.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sadegh Baradaran Mahdavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Close to Negin building, Ahmadieh alley, Taleghani St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8136833691</zip>
        <telephone>+98 31 3236 0339</telephone>
        <email>sadegh.b.mahdavi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sadegh Baradaran Mahdavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Close to Negin building, Ahmadieh alley, Taleghani St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8136833691</zip>
        <telephone>+98 31 3236 0339</telephone>
        <email>sadegh.b.mahdavi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients older than 45 years
Patients diagnosed with knee osteoarthritis according to the American College of Rheumatology criteria with symptoms for at least 3 months
Knee X-ray as grade 2 or 3 of Kellgren-Lawrence (K-L) classification
Patients' willingness to participate in the study after providing complete information about the project's goals</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Clinical findings in other joints of the body such as hip, wrist or spine.
Evidence of neuropathy such as radiculopathy or peripheral neuropathy
Systemic inflammatory disease such as RA, AS
Fibromyalgia or endocrine and metabolic diseases
Corticosteroid use in the past 48 hours or intra-articular injection of Corticosteroid in the past 4 months
Taking NSAIDs in the past week
Psychiatric disease
Severe blood dyscrasia, coagulopathy, current warfarin use
Liver failure or liver tests more than 1.5 times of normal values
Biliary Disease
PUD or reflux history (GERD)
Renal Failure - Uncontrolled hypertension
Lack of medication compliance in the patient</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The itervention group will be orally treated with 250 mg Elartrit capsules (containing Russian olive extract) of Reyhaneh Isfahan Pharmaceutical Company (every 12 hours for 15 days, after meal). In addition, they will be instructed to perform stretching the hamstring and calf muscles as well as the quadriceps strengthening exercises for 30 days in the morning, noon and night, three times in each set and doing those for 30 seconds each time.</i_keyword>
      <i_keyword>The control group will be orally treated with 370 mg curcumin capsules of Razak Pharmaceutical Company (every 12 hours for 15 days, after meal). In addition, they will be instructed to perform stretching the hamstring and calf muscles as well as the quadriceps strengthening exercises for 30 days in the morning, noon and night, three times in each set and doing those for 30 seconds each time.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knee pain intensity. Timepoint: Before treatment, 2 and 4 weeks after treatment. Method of measurement: VAS (Visual Analogue Scale).</prim_outcome>
      <prim_outcome>Symptoms of disease and quality of life. Timepoint: Before treatment, 2 and 4 weeks after treatment. Method of measurement: Knee injury and Osteoarthritis Outcome Score (KOOS).</prim_outcome>
      <prim_outcome>Function. Timepoint: Before treatment, 2 and 4 weeks after treatment. Method of measurement: Roles and Maudsley score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-04</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
